Barclays Maintains Overweight on CVS Health, Lowers Price Target to $107
Benzinga Newsdesk 11 hours ago
Analyst RatingsNewsPrice TargetHot
Barclays analyst Andrew Mok maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $108 to $107.
Barclays analyst Andrew Mok maintains CVS Health (NYSE:CVS) with a Overweight and lowers the price target from $108 to $107.